NovaBay Pharmaceuticals, Inc. (NBY) 10-Year Financial Performance & Capital Metrics

NBY • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutNovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Show more

Revenue $10M -6.4%
EBITDA -$5M -45.7%
Net Income -$7M +25.1%
EPS (Diluted) -2.53 +98.2%
Gross Margin 66.26% +13.9%
EBITDA Margin -55.8% -55.7%
Operating Margin -59.7% -52.2%
Net Margin -73.85% +19.9%
ROE -453.56% -226.2%
ROIC -216.96% -258.1%
Debt/Equity -
Interest Coverage -6.46 -166.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 99 (top 1%)
✓Efficient asset utilization: 2.9x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y24.96%

5Y8.19%

3Y-1.4%

TTM-74.73%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM132.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM101.12%

ROCE

10Y Avg-198.76%

5Y Avg-96.22%

3Y Avg-118.55%

Latest-218.85%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.38M	11.9M	18.23M	12.51M	6.6M	9.93M	10.2M	14.4M	10.46M	9.78M
Revenue Growth %	3.16%	1.72%	0.53%	-0.31%	-0.47%	0.51%	0.03%	0.41%	-0.27%	-0.06%
Cost of Goods Sold+	1.26M	2.46M	2.78M	1.5M	1.74M	3.97M	3.69M	6.62M	4.37M	3.3M
COGS % of Revenue	0.29%	0.21%	0.15%	0.12%	0.26%	0.4%	0.36%	0.46%	0.42%	0.34%
Gross Profit+	3.12M	9.43M	15.45M	11.01M	4.86M	5.96M	6.51M	7.78M	6.08M	6.48M
Gross Margin %	0.71%	0.79%	0.85%	0.88%	0.74%	0.6%	0.64%	0.54%	0.58%	0.66%
Gross Profit Growth %	4.49%	2.02%	0.64%	-0.29%	-0.56%	0.23%	0.09%	0.19%	-0.22%	0.07%
Operating Expenses+	24.13M	20.41M	22.76M	18.88M	14.26M	12.39M	15.38M	22.2M	10.19M	12.32M
OpEx % of Revenue	5.51%	1.72%	1.25%	1.51%	2.16%	1.25%	1.51%	1.54%	0.97%	1.26%
Selling, General & Admin	18.53M	19.04M	22.35M	18.62M	14.08M	12.11M	15.33M	15.29M	10.15M	11.41M
SG&A % of Revenue	4.23%	1.6%	1.23%	1.49%	2.13%	1.22%	1.5%	1.06%	0.97%	1.17%
Research & Development	6.04M	1.37M	410K	259K	184K	285K	44K	174K	34K	42K
R&D % of Revenue	1.38%	0.12%	0.02%	0.02%	0.03%	0.03%	0%	0.01%	0%	0%
Other Operating Expenses	-96K	-68K	12K	19K	0	0	0	6.74M	0	865K
Operating Income+	-21.01M	-10.98M	-7.31M	-7.87M	-9.4M	-6.43M	-8.86M	-14.42M	-4.1M	-5.84M
Operating Margin %	-4.8%	-0.92%	-0.4%	-0.63%	-1.42%	-0.65%	-0.87%	-1%	-0.39%	-0.6%
Operating Income Growth %	-0.25%	0.48%	0.33%	-0.08%	-0.19%	0.32%	-0.38%	-0.63%	0.72%	-0.42%
EBITDA+	-20.85M	-10.87M	-7.22M	-7.61M	-9.34M	-6.38M	-8.74M	-13.93M	-3.75M	-5.46M
EBITDA Margin %	-4.76%	-0.91%	-0.4%	-0.61%	-1.41%	-0.64%	-0.86%	-0.97%	-0.36%	-0.56%
EBITDA Growth %	-0.25%	0.48%	0.34%	-0.05%	-0.23%	0.32%	-0.37%	-0.59%	0.73%	-0.46%
D&A (Non-Cash Add-back)	164K	114K	95K	266K	65K	51K	119K	483K	356K	381K
EBIT	-21.14M	-10.98M	-7.31M	-7.87M	-9.4M	-6.43M	-8.86M	-7.68M	-4.45M	-6.31M
Net Interest Income+	0	0	0	0	-1.05M	0	0	0	-1.69M	-904K
Interest Income	0	0	0	0	-	0	0	0	0	0
Interest Expense	0	0	0	0	1.05M	0	0	0	1.69M	904K
Other Income/Expense	2.04M	-2.17M	-89K	1.33M	-252K	-4.61M	3.04M	3.81M	-2.04M	-1.37M
Pretax Income+	-18.97M	-13.15M	-7.4M	-6.54M	-9.65M	-11.03M	-5.82M	-10.61M	-6.14M	-7.21M
Pretax Margin %	-4.33%	-1.11%	-0.41%	-0.52%	-1.46%	-1.11%	-0.57%	-0.74%	-0.59%	-0.74%
Income Tax+	12K	2K	3K	4K	6K	5K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1.57%	1%
Net Income+	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-9.64M	-7.22M
Net Margin %	-4.33%	-1.11%	-0.41%	-0.52%	-1.46%	-1.11%	-0.57%	-0.74%	-0.92%	-0.74%
Net Income Growth %	-0.25%	0.31%	0.44%	0.12%	-0.48%	-0.14%	0.47%	-0.82%	0.09%	0.25%
Net Income (Continuing)	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-6.14M	-7.21M
Discontinued Operations	0	0	0	0	0	0	0	0	-3.5M	-13K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-694.63	-1047.97	-591.81	-564.17	-593.63	-385.53	-184.09	-353.59	-138.65	-2.53
EPS Growth %	-0.25%	-0.51%	0.44%	0.05%	-0.05%	0.35%	0.52%	-0.92%	0.61%	0.98%
EPS (Basic)	-702.47	-1058.69	-591.81	-473.83	-593.63	-385.53	-184.09	-353.59	-139.14	-2.53
Diluted Shares Outstanding	27.31K	12.55K	12.51K	13.93K	17.67K	28.63K	35.63K	46K	120K	3.4M
Basic Shares Outstanding	27.01K	12.42K	12.51K	11.6K	16.27K	28.63K	31.64K	30K	120K	3.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.53M	14.47M	8.99M	8.61M	9.38M	14.24M	13.17M	11.33M	7.15M	1.94M
Cash & Short-Term Investments	2.38M	9.51M	3.2M	3.18M	6.94M	11.95M	7.5M	5.36M	3.13M	430K
Cash Only	2.38M	9.51M	3.2M	3.18M	6.94M	11.95M	7.5M	5.36M	3.13M	430K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	536K	2.29M	3.71M	3.49M	1.07M	1.11M	1.69M	2.02M	759K	389K
Days Sales Outstanding	44.66	70.1	74.38	101.93	58.96	40.64	60.31	51.09	26.5	14.52
Inventory	1.34M	873K	504K	280K	492K	608K	3.22M	3.44M	2.88M	765K
Days Inventory Outstanding	389.31	129.32	66.08	68	103.33	55.9	318.6	189.42	240.24	84.61
Other Current Assets	261K	165K	347K	279K	159K	102K	129K	159K	81K	158K
Total Non-Current Assets+	550K	910K	1.08M	753K	1.84M	996K	10.81M	5.07M	1.88M	1.49M
Property, Plant & Equipment	395K	371K	471K	201K	1.36M	520K	604K	1.95M	1.38M	1.01M
Fixed Asset Turnover	11.09x	32.07x	38.70x	62.23x	4.85x	19.10x	16.89x	7.39x	7.56x	9.70x
Goodwill	0	0	0	0	0	0	4.53M	348K	0	0
Intangible Assets	0	0	0	0	0	0	5.2M	2.28M	0	0
Long-Term Investments	0	0	0	475K	0	0	0	0	0	477K
Other Non-Current Assets	155K	539K	613K	77K	477K	476K	476K	489K	497K	3K
Total Assets+	5.08M	15.38M	10.08M	9.36M	11.22M	15.24M	23.98M	16.4M	9.03M	3.42M
Asset Turnover	0.86x	0.77x	1.81x	1.34x	0.59x	0.65x	0.43x	0.88x	1.16x	2.86x
Asset Growth %	-0.33%	2.03%	-0.34%	-0.07%	0.2%	0.36%	0.57%	-0.32%	-0.45%	-0.62%
Total Current Liabilities+	4.63M	4.32M	4.98M	3.85M	5.69M	2.83M	3.44M	4.26M	4.28M	2.84M
Accounts Payable	2.48M	455K	466K	551K	331K	302K	1.04M	1.08M	1.13M	623K
Days Payables Outstanding	718.71	67.4	61.1	133.81	69.51	27.77	103.4	59.52	94.36	68.91
Short-Term Debt	0	0	0	0	2.61M	0	105K	0	1.14M	565K
Deferred Revenue (Current)	170K	1000K	1000K	1000K	822K	730K	1000K	1000K	0	488K
Other Current Liabilities	776K	44K	564K	2.45M	37K	0	0	0	1.18M	172K
Current Ratio	0.98x	3.35x	1.81x	2.24x	1.65x	5.03x	3.83x	2.66x	1.67x	0.68x
Quick Ratio	0.69x	3.15x	1.71x	2.16x	1.56x	4.81x	2.89x	1.85x	1.00x	0.41x
Cash Conversion Cycle	-284.74	132.02	79.36	36.12	92.77	68.77	275.51	180.98	172.38	30.22
Total Non-Current Liabilities+	5.54M	3.96M	2.51M	560K	4.56M	87K	10.37M	1.59M	1.44M	709K
Long-Term Debt	1.66M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	505K	87K	246K	1.59M	1.11M	709K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.64M	1.97M	1.97M	560K	4.05M	0	10.12M	0	334K	0
Total Liabilities	10.18M	8.28M	7.49M	4.41M	10.25M	2.92M	13.81M	5.84M	5.72M	3.55M
Total Debt+	1.66M	0	0	0	4.05M	503K	551K	2.04M	2.74M	1.67M
Net Debt	-730K	-9.51M	-3.2M	-3.18M	-2.89M	-11.45M	-6.95M	-3.32M	-390K	1.24M
Debt / Equity	-	-	-	-	4.16x	0.04x	0.05x	0.19x	0.83x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-8.93x	-	-	-	-2.42x	-6.46x
Total Equity+	-5.1M	7.1M	2.59M	4.95M	973K	12.32M	10.17M	10.55M	3.31M	-129K
Equity Growth %	-3.76%	2.39%	-0.63%	0.91%	-0.8%	11.66%	-0.17%	0.04%	-0.69%	-1.04%
Book Value per Share	-186.64	565.86	207.37	355.76	55.08	430.20	285.47	229.43	27.62	-0.04
Total Shareholders' Equity	-5.1M	7.1M	2.59M	4.95M	973K	12.32M	10.17M	10.55M	3.31M	-129K
Common Stock	35K	153K	154K	171K	279K	418K	478K	20K	112K	49K
Retained Earnings	-90.52M	-103.67M	-111.07M	-114.98M	-125.02M	-136.06M	-141.89M	-158.15M	-174.85M	-183.46M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.7M	-149K	-243K	-509K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.56M	-12.13M	-6.27M	-5.57M	-7.93M	-4.72M	-9.19M	-6.65M	-4.26M	-5.18M
Operating CF Margin %	-4.24%	-1.02%	-0.34%	-0.45%	-1.2%	-0.48%	-0.9%	-0.46%	-0.41%	-0.53%
Operating CF Growth %	-0.23%	0.35%	0.48%	0.11%	-0.42%	0.4%	-0.95%	0.28%	0.36%	-0.22%
Net Income	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-6.14M	-7.21M
Depreciation & Amortization	164K	114K	95K	266K	65K	51K	119K	483K	356K	381K
Stock-Based Compensation	1.38M	1.75M	2.04M	594K	621K	701K	1.15M	220K	0	0
Deferred Taxes	0	0	0	0	-849K	0	0	0	0	0
Other Non-Cash Items	-2.15M	2.31M	605K	-1.23M	688K	5.36M	-4.6M	2.72M	1.96M	2.24M
Working Capital Changes	1.02M	-3.16M	-1.6M	1.35M	1.2M	210K	-38K	533K	-433K	-595K
Change in Receivables	-299K	-1.58M	-1.51M	774K	2.32M	-317K	452K	-305K	846K	291K
Change in Inventory	-751K	472K	369K	198K	-212K	-116K	-243K	-217K	162K	-272K
Change in Payables	1.66M	-2.16M	-260K	516K	-862K	321K	-163K	667K	-1.13M	-195K
Cash from Investing+	-86K	-160K	-244K	-44K	-19K	-26K	-12.04M	-112K	-19K	1.06M
Capital Expenditures	-123K	-160K	-244K	-44K	-19K	-26K	-52K	-112K	-19K	-6K
CapEx % of Revenue	0.03%	0.01%	0.01%	0%	0%	0%	0.01%	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	37K	0	0	0	0	0	0	0	0	0
Cash from Financing+	15.6M	19.42M	201K	5.6M	11.7M	9.76M	16.79M	4.63M	1.91M	1.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.43M	7.43M	201K	12K	58K	7.11M	0	1.7M	-181K	-115K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.68M	-12.29M	-6.51M	-5.61M	-7.95M	-4.75M	-9.24M	-6.77M	-4.28M	-5.19M
FCF Margin %	-4.26%	-1.03%	-0.36%	-0.45%	-1.2%	-0.48%	-0.91%	-0.47%	-0.41%	-0.53%
FCF Growth %	-0.24%	0.34%	0.47%	0.14%	-0.42%	0.4%	-0.95%	0.27%	0.37%	-0.21%
FCF per Share	-683.97	-979.76	-520.75	-403.02	-449.90	-165.79	-259.45	-147.09	-35.67	-1.53
FCF Conversion (FCF/Net Income)	0.98x	0.92x	0.85x	0.85x	0.82x	0.43x	1.58x	0.63x	0.44x	0.72x
Interest Paid	0	0	0	0	148K	49K	0	17K	0	0
Taxes Paid	0	0	0	14K	14K	14K	21K	24K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-1313.13%	-152.72%	-173.42%	-325.9%	-166.11%	-51.79%	-102.37%	-139.03%	-453.56%
Return on Invested Capital (ROIC)	-	-	-	-1012.56%	-	-554.6%	-325.25%	-206.92%	-60.58%	-216.96%
Gross Margin	71.22%	79.29%	84.73%	87.98%	73.66%	60.04%	63.85%	54.02%	58.19%	66.26%
Net Margin	-433.07%	-110.54%	-40.61%	-52.33%	-146.36%	-111.12%	-57.08%	-73.65%	-92.2%	-73.85%
Debt / Equity	-	-	-	-	4.16x	0.04x	0.05x	0.19x	0.83x	-
Interest Coverage	-	-	-	-	-8.93x	-	-	-	-2.42x	-6.46x
FCF Conversion	0.98x	0.92x	0.85x	0.85x	0.82x	0.43x	1.58x	0.63x	0.44x	0.72x
Revenue Growth	315.65%	171.56%	53.23%	-31.39%	-47.24%	50.54%	2.72%	41.16%	-27.42%	-6.45%

Revenue by Segment

	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Product Revenue	-	-	-	-	-	9.92M	8.4M	14.37M	14.69M	9.75M
Total Product Revenue Growth	-	-	-	-	-	-	-15.32%	71.18%	2.18%	-33.64%
Avenova Product	-	-	-	11M	4.6M	-	-	100K	-	-
Avenova Product Growth	-	-	-	-	-58.18%	-	-	-	-	-
NeutroPhase	-	-	-	-	-	-	368K	-	-	-
NeutroPhase Growth	-	-	-	-	-	-	-	-	-	-
Samples and Future Products	-	-	-	41K	-	-	-	-	-	-
Samples and Future Products Growth	-	-	-	-	-	-	-	-	-	-
Neutrophase	-	418K	252K	-	-	-	-	-	-	-
Neutrophase Growth	-	-	-39.71%	-	-	-	-	-	-	-
Wound Care	471K	-	-	-	-	-	-	-	-	-
Wound Care Growth	-	-	-	-	-	-	-	-	-	-
Ophthalmology	329K	-	-	-	-	-	-	-	-	-
Ophthalmology Growth	-	-	-	-	-	-	-	-	-	-
Others	249K	-	-	-	-	-	-	-	-	-
Others Growth	-	-	-	-	-	-	-	-	-	-
Dermatology	5K	-	-	-	-	-	-	-	-	-
Dermatology Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NovaBay Pharmaceuticals, Inc. (NBY) reported $2.8M in revenue for fiscal year 2024. This represents a 74% decrease from $11.0M in 2011.

NovaBay Pharmaceuticals, Inc. (NBY) saw revenue decline by 6.4% over the past year.

Yes, NovaBay Pharmaceuticals, Inc. (NBY) is profitable, generating $3.2M in net income for fiscal year 2024 (-73.8% net margin).

Dividend & Returns

NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -453.6%. Negative ROE indicates the company is unprofitable.

NovaBay Pharmaceuticals, Inc. (NBY) had negative free cash flow of $7.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

NovaBay Pharmaceuticals, Inc. (NBY) 10-Year Financial Performance & Capital Metrics

NBY • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $10M -6.4%
EBITDA -$5M -45.7%
Net Income -$7M +25.1%
EPS (Diluted) -2.53 +98.2%
Gross Margin 66.26% +13.9%
EBITDA Margin -55.8% -55.7%
Operating Margin -59.7% -52.2%
Net Margin -73.85% +19.9%
ROE -453.56% -226.2%
ROIC -216.96% -258.1%
Debt/Equity -
Interest Coverage -6.46 -166.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 99 (top 1%)
✓Efficient asset utilization: 2.9x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y24.96%

5Y8.19%

3Y-1.4%

TTM-74.73%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM132.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM101.12%

ROCE

10Y Avg-198.76%

5Y Avg-96.22%

3Y Avg-118.55%

Latest-218.85%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.38M	11.9M	18.23M	12.51M	6.6M	9.93M	10.2M	14.4M	10.46M	9.78M
Revenue Growth %	3.16%	1.72%	0.53%	-0.31%	-0.47%	0.51%	0.03%	0.41%	-0.27%	-0.06%
Cost of Goods Sold+	1.26M	2.46M	2.78M	1.5M	1.74M	3.97M	3.69M	6.62M	4.37M	3.3M
COGS % of Revenue	0.29%	0.21%	0.15%	0.12%	0.26%	0.4%	0.36%	0.46%	0.42%	0.34%
Gross Profit+	3.12M	9.43M	15.45M	11.01M	4.86M	5.96M	6.51M	7.78M	6.08M	6.48M
Gross Margin %	0.71%	0.79%	0.85%	0.88%	0.74%	0.6%	0.64%	0.54%	0.58%	0.66%
Gross Profit Growth %	4.49%	2.02%	0.64%	-0.29%	-0.56%	0.23%	0.09%	0.19%	-0.22%	0.07%
Operating Expenses+	24.13M	20.41M	22.76M	18.88M	14.26M	12.39M	15.38M	22.2M	10.19M	12.32M
OpEx % of Revenue	5.51%	1.72%	1.25%	1.51%	2.16%	1.25%	1.51%	1.54%	0.97%	1.26%
Selling, General & Admin	18.53M	19.04M	22.35M	18.62M	14.08M	12.11M	15.33M	15.29M	10.15M	11.41M
SG&A % of Revenue	4.23%	1.6%	1.23%	1.49%	2.13%	1.22%	1.5%	1.06%	0.97%	1.17%
Research & Development	6.04M	1.37M	410K	259K	184K	285K	44K	174K	34K	42K
R&D % of Revenue	1.38%	0.12%	0.02%	0.02%	0.03%	0.03%	0%	0.01%	0%	0%
Other Operating Expenses	-96K	-68K	12K	19K	0	0	0	6.74M	0	865K
Operating Income+	-21.01M	-10.98M	-7.31M	-7.87M	-9.4M	-6.43M	-8.86M	-14.42M	-4.1M	-5.84M
Operating Margin %	-4.8%	-0.92%	-0.4%	-0.63%	-1.42%	-0.65%	-0.87%	-1%	-0.39%	-0.6%
Operating Income Growth %	-0.25%	0.48%	0.33%	-0.08%	-0.19%	0.32%	-0.38%	-0.63%	0.72%	-0.42%
EBITDA+	-20.85M	-10.87M	-7.22M	-7.61M	-9.34M	-6.38M	-8.74M	-13.93M	-3.75M	-5.46M
EBITDA Margin %	-4.76%	-0.91%	-0.4%	-0.61%	-1.41%	-0.64%	-0.86%	-0.97%	-0.36%	-0.56%
EBITDA Growth %	-0.25%	0.48%	0.34%	-0.05%	-0.23%	0.32%	-0.37%	-0.59%	0.73%	-0.46%
D&A (Non-Cash Add-back)	164K	114K	95K	266K	65K	51K	119K	483K	356K	381K
EBIT	-21.14M	-10.98M	-7.31M	-7.87M	-9.4M	-6.43M	-8.86M	-7.68M	-4.45M	-6.31M
Net Interest Income+	0	0	0	0	-1.05M	0	0	0	-1.69M	-904K
Interest Income	0	0	0	0	-	0	0	0	0	0
Interest Expense	0	0	0	0	1.05M	0	0	0	1.69M	904K
Other Income/Expense	2.04M	-2.17M	-89K	1.33M	-252K	-4.61M	3.04M	3.81M	-2.04M	-1.37M
Pretax Income+	-18.97M	-13.15M	-7.4M	-6.54M	-9.65M	-11.03M	-5.82M	-10.61M	-6.14M	-7.21M
Pretax Margin %	-4.33%	-1.11%	-0.41%	-0.52%	-1.46%	-1.11%	-0.57%	-0.74%	-0.59%	-0.74%
Income Tax+	12K	2K	3K	4K	6K	5K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1.57%	1%
Net Income+	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-9.64M	-7.22M
Net Margin %	-4.33%	-1.11%	-0.41%	-0.52%	-1.46%	-1.11%	-0.57%	-0.74%	-0.92%	-0.74%
Net Income Growth %	-0.25%	0.31%	0.44%	0.12%	-0.48%	-0.14%	0.47%	-0.82%	0.09%	0.25%
Net Income (Continuing)	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-6.14M	-7.21M
Discontinued Operations	0	0	0	0	0	0	0	0	-3.5M	-13K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-694.63	-1047.97	-591.81	-564.17	-593.63	-385.53	-184.09	-353.59	-138.65	-2.53
EPS Growth %	-0.25%	-0.51%	0.44%	0.05%	-0.05%	0.35%	0.52%	-0.92%	0.61%	0.98%
EPS (Basic)	-702.47	-1058.69	-591.81	-473.83	-593.63	-385.53	-184.09	-353.59	-139.14	-2.53
Diluted Shares Outstanding	27.31K	12.55K	12.51K	13.93K	17.67K	28.63K	35.63K	46K	120K	3.4M
Basic Shares Outstanding	27.01K	12.42K	12.51K	11.6K	16.27K	28.63K	31.64K	30K	120K	3.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.53M	14.47M	8.99M	8.61M	9.38M	14.24M	13.17M	11.33M	7.15M	1.94M
Cash & Short-Term Investments	2.38M	9.51M	3.2M	3.18M	6.94M	11.95M	7.5M	5.36M	3.13M	430K
Cash Only	2.38M	9.51M	3.2M	3.18M	6.94M	11.95M	7.5M	5.36M	3.13M	430K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	536K	2.29M	3.71M	3.49M	1.07M	1.11M	1.69M	2.02M	759K	389K
Days Sales Outstanding	44.66	70.1	74.38	101.93	58.96	40.64	60.31	51.09	26.5	14.52
Inventory	1.34M	873K	504K	280K	492K	608K	3.22M	3.44M	2.88M	765K
Days Inventory Outstanding	389.31	129.32	66.08	68	103.33	55.9	318.6	189.42	240.24	84.61
Other Current Assets	261K	165K	347K	279K	159K	102K	129K	159K	81K	158K
Total Non-Current Assets+	550K	910K	1.08M	753K	1.84M	996K	10.81M	5.07M	1.88M	1.49M
Property, Plant & Equipment	395K	371K	471K	201K	1.36M	520K	604K	1.95M	1.38M	1.01M
Fixed Asset Turnover	11.09x	32.07x	38.70x	62.23x	4.85x	19.10x	16.89x	7.39x	7.56x	9.70x
Goodwill	0	0	0	0	0	0	4.53M	348K	0	0
Intangible Assets	0	0	0	0	0	0	5.2M	2.28M	0	0
Long-Term Investments	0	0	0	475K	0	0	0	0	0	477K
Other Non-Current Assets	155K	539K	613K	77K	477K	476K	476K	489K	497K	3K
Total Assets+	5.08M	15.38M	10.08M	9.36M	11.22M	15.24M	23.98M	16.4M	9.03M	3.42M
Asset Turnover	0.86x	0.77x	1.81x	1.34x	0.59x	0.65x	0.43x	0.88x	1.16x	2.86x
Asset Growth %	-0.33%	2.03%	-0.34%	-0.07%	0.2%	0.36%	0.57%	-0.32%	-0.45%	-0.62%
Total Current Liabilities+	4.63M	4.32M	4.98M	3.85M	5.69M	2.83M	3.44M	4.26M	4.28M	2.84M
Accounts Payable	2.48M	455K	466K	551K	331K	302K	1.04M	1.08M	1.13M	623K
Days Payables Outstanding	718.71	67.4	61.1	133.81	69.51	27.77	103.4	59.52	94.36	68.91
Short-Term Debt	0	0	0	0	2.61M	0	105K	0	1.14M	565K
Deferred Revenue (Current)	170K	1000K	1000K	1000K	822K	730K	1000K	1000K	0	488K
Other Current Liabilities	776K	44K	564K	2.45M	37K	0	0	0	1.18M	172K
Current Ratio	0.98x	3.35x	1.81x	2.24x	1.65x	5.03x	3.83x	2.66x	1.67x	0.68x
Quick Ratio	0.69x	3.15x	1.71x	2.16x	1.56x	4.81x	2.89x	1.85x	1.00x	0.41x
Cash Conversion Cycle	-284.74	132.02	79.36	36.12	92.77	68.77	275.51	180.98	172.38	30.22
Total Non-Current Liabilities+	5.54M	3.96M	2.51M	560K	4.56M	87K	10.37M	1.59M	1.44M	709K
Long-Term Debt	1.66M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	505K	87K	246K	1.59M	1.11M	709K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.64M	1.97M	1.97M	560K	4.05M	0	10.12M	0	334K	0
Total Liabilities	10.18M	8.28M	7.49M	4.41M	10.25M	2.92M	13.81M	5.84M	5.72M	3.55M
Total Debt+	1.66M	0	0	0	4.05M	503K	551K	2.04M	2.74M	1.67M
Net Debt	-730K	-9.51M	-3.2M	-3.18M	-2.89M	-11.45M	-6.95M	-3.32M	-390K	1.24M
Debt / Equity	-	-	-	-	4.16x	0.04x	0.05x	0.19x	0.83x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-8.93x	-	-	-	-2.42x	-6.46x
Total Equity+	-5.1M	7.1M	2.59M	4.95M	973K	12.32M	10.17M	10.55M	3.31M	-129K
Equity Growth %	-3.76%	2.39%	-0.63%	0.91%	-0.8%	11.66%	-0.17%	0.04%	-0.69%	-1.04%
Book Value per Share	-186.64	565.86	207.37	355.76	55.08	430.20	285.47	229.43	27.62	-0.04
Total Shareholders' Equity	-5.1M	7.1M	2.59M	4.95M	973K	12.32M	10.17M	10.55M	3.31M	-129K
Common Stock	35K	153K	154K	171K	279K	418K	478K	20K	112K	49K
Retained Earnings	-90.52M	-103.67M	-111.07M	-114.98M	-125.02M	-136.06M	-141.89M	-158.15M	-174.85M	-183.46M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.7M	-149K	-243K	-509K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.56M	-12.13M	-6.27M	-5.57M	-7.93M	-4.72M	-9.19M	-6.65M	-4.26M	-5.18M
Operating CF Margin %	-4.24%	-1.02%	-0.34%	-0.45%	-1.2%	-0.48%	-0.9%	-0.46%	-0.41%	-0.53%
Operating CF Growth %	-0.23%	0.35%	0.48%	0.11%	-0.42%	0.4%	-0.95%	0.28%	0.36%	-0.22%
Net Income	-18.97M	-13.15M	-7.4M	-6.54M	-9.66M	-11.04M	-5.82M	-10.61M	-6.14M	-7.21M
Depreciation & Amortization	164K	114K	95K	266K	65K	51K	119K	483K	356K	381K
Stock-Based Compensation	1.38M	1.75M	2.04M	594K	621K	701K	1.15M	220K	0	0
Deferred Taxes	0	0	0	0	-849K	0	0	0	0	0
Other Non-Cash Items	-2.15M	2.31M	605K	-1.23M	688K	5.36M	-4.6M	2.72M	1.96M	2.24M
Working Capital Changes	1.02M	-3.16M	-1.6M	1.35M	1.2M	210K	-38K	533K	-433K	-595K
Change in Receivables	-299K	-1.58M	-1.51M	774K	2.32M	-317K	452K	-305K	846K	291K
Change in Inventory	-751K	472K	369K	198K	-212K	-116K	-243K	-217K	162K	-272K
Change in Payables	1.66M	-2.16M	-260K	516K	-862K	321K	-163K	667K	-1.13M	-195K
Cash from Investing+	-86K	-160K	-244K	-44K	-19K	-26K	-12.04M	-112K	-19K	1.06M
Capital Expenditures	-123K	-160K	-244K	-44K	-19K	-26K	-52K	-112K	-19K	-6K
CapEx % of Revenue	0.03%	0.01%	0.01%	0%	0%	0%	0.01%	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	37K	0	0	0	0	0	0	0	0	0
Cash from Financing+	15.6M	19.42M	201K	5.6M	11.7M	9.76M	16.79M	4.63M	1.91M	1.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.43M	7.43M	201K	12K	58K	7.11M	0	1.7M	-181K	-115K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.68M	-12.29M	-6.51M	-5.61M	-7.95M	-4.75M	-9.24M	-6.77M	-4.28M	-5.19M
FCF Margin %	-4.26%	-1.03%	-0.36%	-0.45%	-1.2%	-0.48%	-0.91%	-0.47%	-0.41%	-0.53%
FCF Growth %	-0.24%	0.34%	0.47%	0.14%	-0.42%	0.4%	-0.95%	0.27%	0.37%	-0.21%
FCF per Share	-683.97	-979.76	-520.75	-403.02	-449.90	-165.79	-259.45	-147.09	-35.67	-1.53
FCF Conversion (FCF/Net Income)	0.98x	0.92x	0.85x	0.85x	0.82x	0.43x	1.58x	0.63x	0.44x	0.72x
Interest Paid	0	0	0	0	148K	49K	0	17K	0	0
Taxes Paid	0	0	0	14K	14K	14K	21K	24K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-1313.13%	-152.72%	-173.42%	-325.9%	-166.11%	-51.79%	-102.37%	-139.03%	-453.56%
Return on Invested Capital (ROIC)	-	-	-	-1012.56%	-	-554.6%	-325.25%	-206.92%	-60.58%	-216.96%
Gross Margin	71.22%	79.29%	84.73%	87.98%	73.66%	60.04%	63.85%	54.02%	58.19%	66.26%
Net Margin	-433.07%	-110.54%	-40.61%	-52.33%	-146.36%	-111.12%	-57.08%	-73.65%	-92.2%	-73.85%
Debt / Equity	-	-	-	-	4.16x	0.04x	0.05x	0.19x	0.83x	-
Interest Coverage	-	-	-	-	-8.93x	-	-	-	-2.42x	-6.46x
FCF Conversion	0.98x	0.92x	0.85x	0.85x	0.82x	0.43x	1.58x	0.63x	0.44x	0.72x
Revenue Growth	315.65%	171.56%	53.23%	-31.39%	-47.24%	50.54%	2.72%	41.16%	-27.42%	-6.45%

Revenue by Segment

	2014	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Product Revenue	-	-	-	-	-	9.92M	8.4M	14.37M	14.69M	9.75M
Total Product Revenue Growth	-	-	-	-	-	-	-15.32%	71.18%	2.18%	-33.64%
Avenova Product	-	-	-	11M	4.6M	-	-	100K	-	-
Avenova Product Growth	-	-	-	-	-58.18%	-	-	-	-	-
NeutroPhase	-	-	-	-	-	-	368K	-	-	-
NeutroPhase Growth	-	-	-	-	-	-	-	-	-	-
Samples and Future Products	-	-	-	41K	-	-	-	-	-	-
Samples and Future Products Growth	-	-	-	-	-	-	-	-	-	-
Neutrophase	-	418K	252K	-	-	-	-	-	-	-
Neutrophase Growth	-	-	-39.71%	-	-	-	-	-	-	-
Wound Care	471K	-	-	-	-	-	-	-	-	-
Wound Care Growth	-	-	-	-	-	-	-	-	-	-
Ophthalmology	329K	-	-	-	-	-	-	-	-	-
Ophthalmology Growth	-	-	-	-	-	-	-	-	-	-
Others	249K	-	-	-	-	-	-	-	-	-
Others Growth	-	-	-	-	-	-	-	-	-	-
Dermatology	5K	-	-	-	-	-	-	-	-	-
Dermatology Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NovaBay Pharmaceuticals, Inc. (NBY) reported $2.8M in revenue for fiscal year 2024. This represents a 74% decrease from $11.0M in 2011.

NovaBay Pharmaceuticals, Inc. (NBY) saw revenue decline by 6.4% over the past year.

Yes, NovaBay Pharmaceuticals, Inc. (NBY) is profitable, generating $3.2M in net income for fiscal year 2024 (-73.8% net margin).

Dividend & Returns

NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -453.6%. Negative ROE indicates the company is unprofitable.

NovaBay Pharmaceuticals, Inc. (NBY) had negative free cash flow of $7.0M in fiscal year 2024, likely due to heavy capital investments.